<DOC>
	<DOCNO>NCT01700179</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability efficacy 12 week treatment ACH-0143102 ribavirin GT1b , treatment-naive , HCV subject .</brief_summary>
	<brief_title>Evaluation Safety Tolerability Antiviral Activity ACH-0143102 Plus RBV Treatment Naive HCV GT1b Subjects</brief_title>
	<detailed_description>A phase 1b , pilot study evaluate safety , tolerability antiviral activity oral ACH-0143102 administer combination ribavirin 12 week treatment naive subject chronic hepatitis C virus infection genotype 1b .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Males females 18 year old Clinical diagnosis hepatitis C genotype 1b Chronic hepatitis C treatment naive subject IL28B genotype CC HCV RNA &gt; 10000 IU/mL screen Females must willing use two effective method contraception dose period six month last dose ribavirin . Male patient must willing use effective barrier method contraception throughout dose period six month last dose ribavirin . Males must agree donate sperm enrol study six month last dose ribavirin . Willing participate study activity study requirement . BMI &gt; 36 Pregnant nursing female Clinically significant laboratory abnormality screen Previous participation clinical trial protease inhibitor and/or NS5A inhibitor HIV infection liver diseases Positive Hepatitis B Surface Antigen Liver cirrhosis Uncontrolled psychiatric disease Clinical evidence chronic cardiac disease History malignancy organ system within 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>